Stimuliver
David Hay has a rich background in academia and research, holding various positions such as Chair of Tissue Engineering at the University of Edinburgh, Professor at Zhejiang University, and Founder, Chairman, and CEO of Stimuliver. David has also co-founded Stemnovate and HigherSteaks, contributing to innovative technologies in drug screening and cell culture. With a PhD in Molecular and Cellular Biology from the University of St Andrews, David Hay has made significant contributions to fields such as stem cell biology and tissue engineering.
This person is not in any teams
This person is not in any offices
Stimuliver
Liver disease kills approximately two million people per annum. Although organ transplant is a viable option to treat disease, many patients are not candidates for this type of treatment or die on the transplant waiting list. Stimuliver is developing a disruptive liver implant to treat critically failing liver function in humans. The implant will be placed underneath the skin to ‘top up’ the patient’s reduced liver function. Lab engineered liver tissue will be produced from human stem cells, providing a scalable and renewable source of human liver tissue. The development of the liver implant to clinical grade will provide patients with a renewable treatment option for their disease.